MYOPIC CHOROIDAL NEOVASCULARIZATION
Clinical trials for MYOPIC CHOROIDAL NEOVASCULARIZATION explained in plain language.
Never miss a new study
Get alerted when new MYOPIC CHOROIDAL NEOVASCULARIZATION trials appear
Sign up with your email to follow new studies for MYOPIC CHOROIDAL NEOVASCULARIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug faricimab takes on leading cause of blindness in nearsighted people
Disease control CompletedThis study tested a drug called faricimab (VABYSMO®) against an existing treatment (ranibizumab) for people with vision loss caused by abnormal blood vessels growing in the back of the eye due to severe nearsightedness. The trial involved 280 participants who received either fari…
Matched conditions: MYOPIC CHOROIDAL NEOVASCULARIZATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New syringe design makes eye injection easier for doctors
Disease control CompletedThis study tested whether a pre-filled syringe of the medicine SB11 (a biosimilar to ranibizumab) is easy for eye doctors to use. Thirty adults with wet age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received on…
Matched conditions: MYOPIC CHOROIDAL NEOVASCULARIZATION
Phase: PHASE2 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC